Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Pasithea Therapeutics Corp. (KTTA)

Pasithea Therapeutics gets Nasdaq bid price extension to February 16, 2027

Negative Impact 4 of 5 legal/regulatory Written later

Pasithea Therapeutics Corp. received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, moving the deadline from August 19, 2026 to February 16, 2027. The company says it may consider a reverse stock split, and if it does not regain compliance, Nasdaq could begin delisting proceedings, though the company says there is no assurance it will meet the new deadline.

Key points

  • Nasdaq letter dated February 20, 2026 flagged closing bid price below $1.00 for 30 consecutive business days.
  • Original compliance deadline was August 19, 2026; extension granted in an August 20, 2026 Nasdaq letter to February 16, 2027.
  • Company may consider a reverse stock split; if not compliant by the deadline, Nasdaq would issue a delisting notice that the company could appeal to a hearings panel.

The filing

CompanyPasithea Therapeutics Corp. (KTTA)
Form8-K, current report
Filed with the SECAug 21, 2026, 5:05 PM ET
Accession number0001213900-26-092672

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.